Related Experiment Video
Updated: Aug 6, 2026
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Evaluation of surgical approach and adjuvant therapy in uterine sarcomas: an 11-year population-based study
Filip Herbst1, Erik Holmberg2, Louise Moberg3
1Department of Obstetrics and Gynecology, Skåne University Hospital Lund, Lund University, Klinikgatan 12, Lund, 221 85, Sweden. filip.herbst@med.lu.se.
Background:
Uterine sarcomas are rare and high-quality evidence regarding optimal treatment is limited and difficult to produce.
Methods:
A total of 618 patients with uterine sarcoma were identified in the Swedish Quality Registry for Gynecologic Cancer (SQRGC) from 2010 to 2020. Survival was analyzed according to stage, histology and treatment modality.
Results:
The incidence of uterine sarcoma was 1.43 per 100,000 woman-years. Overall survival after 1 and 5 years was 75.9% and 44.1% respectively, with survival primarily influenced by stage, age and histological type. Adjuvant chemotherapy was not associated with improved survival, neither in localized nor advanced disease. Among patients with stage I disease, overall survival was higher after minimally invasive surgery (MIS) 81%, compared to open surgery 57% (p = 0.007); however, after entropy balancing no significant difference was observed.
Conclusions:
MIS showed comparable survival to open surgery in early-stage uterine sarcomas, with a non-significant trend toward improved survival. Entropy balancing supported this finding but residual confounding and selection bias cannot be excluded due to the observational design. Adjuvant chemotherapy was not associated with improved survival in uterine sarcoma patients overall or in leiomyosarcomas specifically, neither in localized nor advanced disease.
